

# Qualiveen Questionnaire

## Assessment Overview

### Assessment Area

**ICF Domain:**

Quality of Life

**Subscales (domains):**

Limitations/Inconvenience

Constraints/Restrictions

Fears

Feelings/Impact on Daily Life

### You Will Need

**Length:**

Qualiveen-30: 30 minutes, 30 items

**Scoring:**

The questionnaire is based on a 5 point Likert scale. Each domain score is calculated as an average of the scores for the domain items. An overall (averaged) score can also be calculated. Lower scores on this questionnaire indicate higher quality of life.

### Summary

The Qualiveen Questionnaire is a self-report or interview-based measure developed as a condition-specific quality of life measure that could be used in international multi-centre trials, for individuals with SCI who have urinary disorders. The Qualiveen Questionnaire contains 4 domains: Limitations/Inconvenience, Constraints/Restrictions, Fears, Feelings/Impact on Daily Life. The Qualiveen Questionnaire has 3 versions (in order of development): Qualiveen (40 items), Qualiveen-30, SF-Qualiveen (8 items).

### Availability

Available for purchase at <https://eprovide.mapi-trust.org/>

**Languages:** English, French, Spanish, Portuguese, Dutch, German, Italian, Arabic, Persian and Turkish

## Assessment Interpretability

### Minimal Clinically Important Difference

Not established in SCI

### Statistical Error

Not established in SCI

### Typical Values

See Research Summary for mean scores by populations: Sex, Age, Paraplegia/Tetraplegia, and Cauda equina syndrome.

## Measurement Properties

### Validity – **Low** to **Moderate**

**Low to Moderate correlation with Short Form 12 (SF-12):**

Physical Component = -0.32

Mental Component = -0.29

(Persian Qualiveen-30; Nikfallah et al., 2015; N=154, 89 male, 80 SCI, 74 MS, outpatient, no information on injury types)

**Number of studies reporting validity data: 2**

### Reliability – **High**

**High Test-retest Reliability (3-week interval):**

ICC = 0.97

**High Internal Consistency:**

$\alpha = 0.95$

(Persian Qualiveen-30; Nikfallah et al., 2015; N=154, 89 male, 80 SCI, 74 MS, outpatient, no information on injury types)

**Number of studies reporting reliability data: 2**

## Responsiveness

### **Floor/Ceiling Effect:**

Total Score: 0% ceiling & floor

For 5 items: 0.7-10.5% floor & 0.7-3.5% ceiling

(Persian Qualiveen-30; Nikfallah et al., 2015; N=154, 89 male, 80 SCI, 74 MS, outpatient, no information on injury types)

### **Effect Size:**

Not established in SCI

**Number of studies reporting responsiveness data: 2**